Skip to content

Central Apnea in Patients Receiving Ticagrelor

Central Apnea in Patients Receiving Ticagrelor

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03540459
Enrollment
50
Registered
2018-05-30
Start date
2018-04-01
Completion date
2020-09-30
Last updated
2020-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Brief summary

all patients with a left ventricular ejection fraction superior or equal to 50% less than 2 years after an acute coronary event and receiving ticagrelor will undergo a sleep polygraphy

Detailed description

all patients with a left ventricular ejection fraction superior or equal to 50% less than 2 years after an acute coronary event and receiving ticagrelor will undergo a sleep polygraphy the main objective of the study will be to look for central sleep apnea

Interventions

DIAGNOSTIC_TESTsleep polygraphy

sleep polygraphy (one night) in all included patients

Sponsors

Les Grands Prés
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* patient receiving ticagrelor 10 days to 2 years after an acute coronary syndrome

Exclusion criteria

* left ventricular ejection fraction \< 50% * patients refusal

Design outcomes

Primary

MeasureTime frameDescription
central apnea indexat baselinemean central apnea index: apnea hypopnea index (AHI) is the scale commonly used to assess sleep disordered breathing.This scale includes central and obstructive apnea and hypopnea. The main outcome will be the central apnea index: number of central apnea per hour

Secondary

MeasureTime frameDescription
global apnea hypopnea indexbaselinenumber of apnea and hypopnea per our

Countries

France

Contacts

Primary Contactphilippe meurin, MD
philippemeurin@hotmail.com+33674003218
Backup Contactjean yves Tabet
jtabet@free.fr0033608352073

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026